New hemophilia drug aims to outperform current standard
NCT ID NCT07416604
Summary
This study will test if a new preventive drug called NXT007 works better than the current standard treatment, emicizumab, at reducing bleeding episodes in people with hemophilia A. It will involve 360 participants aged 12 and older who have hemophilia A, some with and some without inhibitors. The main goal is to see which drug leads to fewer bleeds that need treatment over the study period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.